Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: A non-randomised, open label, adaptive dose-finding trial

Autor: Todd, John A., Evangelou, Marina, Cutler, Antony J., Pekalski, Marcin L., Walker, Neil M., Stevens, Helen E., Porter, Linsey, Smyth, Deborah J., Rainbow, Daniel B., Ferreira, Ricardo C., Esposito, Laura, Hunter, Kara M. D., Loudon, Kevin, Irons, Kathryn, Yang, Jennie H., Bell, Charles J. M., Schuilenburg, Helen, Heywood, James, Challis, Ben, Neupane, Sankalpa, Clarke, Pamela, Coleman, Gillian, Dawson, Sarah, Goymer, Donna, Anselmiova, Katerina, Kennet, Jane, Brown, Judy, Caddy, Sarah L., Lu, Jia, Greatorex, Jane, Goodfellow, Ian, Wallace, Chris, Tree, Tim I., Evans, Mark, Mander, Adrian P., Bond, Simon, Wicker, Linda S., Waldron-Lynch, Frank

Publikováno v: PLoS Medicine
PLoS Medicine, Vol 13, Iss 10, p e1002139 (2016)
Todd, J A, Evangelou, M, Cutler, A J, Pekalski, M L, Walker, N M, Stevens, H E, Porter, L, Smyth, D J, Rainbow, D B, Ferreira, R C, Esposito, L, Hunter, K M D, Loudon, K, Irons, K, Yang, J H, Bell, C J M, Schuilenburg, H, Heywood, J, Challis, B, Neupane, S, Clarke, P, Coleman, G, Dawson, S, Goymer, D, Anselmiova, K, Kennet, J, Brown, J, Caddy, S L, Lu, J, Greatorex, J, Goodfellow, I, Wallace, C, Tree, T I, Evans, M, Mander, A P, Bond, S, Wicker, L S & Waldron-Lynch, F 2016, ' Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2 : A Non-Randomised, Open Label, Adaptive Dose-Finding Trial ', PL o S Medicine, vol. 13, no. 10, e1002139 . https://doi.org/10.1371/journal.pmed.1002139

Background Interleukin-2 (IL-2) has an essential role in the expansion and function of CD4+ regulatory T cells (Tregs). Tregs reduce tissue damage by limiting the immune response following infection and regulate autoreactive CD4+ effector T cells (Te

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e1c8df238f9bd0b4b509e1bf7c865862
https://ora.ox.ac.uk/objects/uuid:01a52af1-ff42-4256-99be-80df2bfa4ad6

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial

Autor: Todd, John A, Evangelou, Marina, Cutler, Antony J, Pekalski, Marcin L, Walker, Neil M, Stevens, Helen E, Porter, Linsey, Smyth, Deborah J, Rainbow, Daniel B, Ferreira, Ricardo C, Esposito, Laura, Hunter, Kara MD, Loudon, Kevin, Irons, Kathryn, Yang, Jennie H, Bell, Charles JM, Schuilenburg, Helen, Heywood, James, Challis, Ben, Neupane, Sankalpa, Clarke, Pamela, Coleman, Gillian, Dawson, Sarah, Goymer, Donna, Anselmiova, Katerina, Kennet, Jane, Brown, Judy, Caddy, Sarah L, Lu, Jia, Greatorex, Jane, Goodfellow, Ian, Wallace, Chris, Tree, Tim I, Evans, Mark, Mander, Adrian P, Bond, Simon, Wicker, Linda S, Waldron-Lynch, Frank

BACKGROUND: Interleukin-2 (IL-2) has an essential role in the expansion and function of CD4+ regulatory T cells (Tregs). Tregs reduce tissue damage by limiting the immune response following infection and regulate autoreactive CD4+ effector T cells (T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5116d1b5807968bbe212eda6d0abd7e8